ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026
Evaluating the efficacy and safety of Stapokibart (CM310) in the treatment of uncontrolled seasonal allergic rhinitis based on real-world research.
Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evaluating large language models in chronic rhinosinusitis: methodological constraints and the need for clinically grounded validation.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
- Comment on 'Evaluating the efficacy and readability of advanced large language models in responding to patients' frequently asked questions about chronic rhinosinusitis: a comparative analysis'.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMore than 60% of seasonal allergic rhinitis (SAR) patients still remain inadequately control even after receiving standard-of-care (SoC). Recently, Stapokibart (CM310), has demonstrated efficacy in randomized controlled trials, but real-world evidence for SoC-refractory SAR is still insufficient.
methodsThis prospective real-world study enrolled 127 patients with moderate-to-severe SAR. All participants received Stapokibart treatment (600 mg subcutaneous loading dose, followed by 300 mg at week 2). Efficacy outcomes included the reflective total nasal /ocular symptom score (rTNSS/rTOSS), visual analogue scale (VAS), and rhinoconjunctivitis quality of Life questionnaire (RQLQ) change at weeks 2 and 12. Statistical analyses used Wilcoxon signed-rank test (Bonferroni-corrected) and generalized estimating equations (GEE).
resultsAll outcomes improved significantly at Weeks 2 and 12 vs. baseline (all P < .001). Median rTNSS decreased from 8.00 (IQR:7.00–10.00) to 4.00 (2.00–5.00) at Week 2 and remained stable; rTOSS fell to 0.00 (0.00–1.75) at Week 12. VAS and RQLQ showed progressive improvements. Only 8 (6.3%) patients reported mild, transient injection-site adverse events; no severe events occurred.
conclusionStapokibart is clinically effective and well-tolerated in SoC-refractory SAR, with sustained benefits up to 12 weeks. It is a valuable treatment for heterogeneous patients, supporting its routine clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.